ALFA - Acute Leukemia French Association

What ALFA - Acute Leukemia French Association does

ALFA (Acute Leukemia French Association) is a French non-profit association (Loi 1901), founded in 1998 and headquartered at the Institut de Recherche Saint-Louis, Hôpital Saint-Louis in Paris, dedicated to the treatment and research of adult Acute Myeloid Leukemia (AML). The association is a multidisciplinary network comprising clinicians, biologists, and clinical research assistants operating across 33 member centers throughout metropolitan France and La Réunion. Its core activity is the design and coordination of clinical trials, the standardization of diagnostic and monitoring protocols, and the dissemination of research findings through peer-reviewed publication and participation in major hematology congresses (ASH, EHA, SFH).

ALFA's infrastructure is organized around six centralized components: a molecular biology laboratory and centralized molecular MRD monitoring at Lille CHRU (Pr. Claude Preudhomme), a centralized cytogenetic review at Hôpital André Mignot in Versailles (Dr. Christine Terre), a biobank at Lille CHRU, a multiparameter flow cytometry (CMF) network for measurable residual disease (MRD) monitoring co-led from Lyon and Lille, an independent data center and biostatistics unit at Hôpital Saint-Louis (Prs. Sylvie Chevret and Matthieu Resche-Rigon), and a translational research laboratory network led by Pr. Raphaël Itzykson and Dr. Meyling Cheok. The association also operates a Health Data Warehouse (Entrepôt de Données de Santé / EDS) for structured leukemia data management. These protocols, particularly MRD flow cytometry using LAIP/Dfn and LSC approaches, are aligned with European LeukemiaNet (ELN) consensus guidelines; ALFA's leadership co-authored the 2021 ELN MRD consensus update.

ALFA is a founding member of the Carnot OPALE Institute (labeled February 2020 by the French Ministry for Higher Education, Research and Innovation), which aligns 17 research teams, 7 cooperative groups including ALFA, FILO, GRAALL, GFM, FIM, and SFCE, and 4 R&D platforms under a single industrial-partnership framework. As a non-profit, ALFA generates no commercial revenue; operations are funded through research grants and pharmaceutical-sponsored clinical trials, with membership free for clinicians, biologists, and clinical research assistants. Governance rests on a Board of Directors and Scientific Committee, led by President Pr. Hervé Dombret, Vice-President Pr. Claude Preudhomme, Treasurer Lauris Gastaud, and Coordinator Karine Celli-Lebras.

Name

ALFA - Acute Leukemia French Association

Legal name

Acute Leukemia French Association (ALFA)

Website

https://alfa-leukemia.org

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

ALFA (Acute Leukemia French Association) is a Paris-based non-profit research association (Loi 1901) coordinating 33 French clinical and research centers dedicated to adult Acute Myeloid Leukemia (AML) trials, centralized molecular and cytogenetic diagnostics, MRD monitoring, biobanking, and translational research.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAGAEAB

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAGAEAG

Bioanalytical & PK/PD Sample Analysis (Trial Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAGADAA

Bioanalytical Testing (PK/ADA/NAb)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Testing & Analytical Services

Keywords

• Clinical research services
• Leukemia clinical trials
• MRD flow cytometry
• Centralized biobanking
• Translational hematology

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Distribution channels1 record

Marketing channels4 records

Core offering

ALFA is a multidisciplinary non-profit association that coordinates clinical trials and centralized research infrastructure for the treatment of adult Acute Myeloid Leukemia (AML) across 33 French centers. It provides centralized cytogenetic review, molecular biology testing, measurable residual disease (MRD) flow cytometry monitoring, a centralized biobank, an independent data center and biostatistics unit, and a translational research network. Services are accessed by member clinicians, biologists, and clinical research assistants who participate in collaborative AML research and treatment protocols aligned with European LeukemiaNet guidelines.

Product overview

ALFA (Acute Leukemia French Association) is a multidisciplinary nonprofit research association (Loi 1901) focused on the treatment of Acute Myeloid Leukemia (AML) in adults. The organization does not offer commercial products or services; rather, it conducts clinical and biological research, coordinates clinical trials, manages a health data warehouse (Entrepôt de Données de Santé - EDS), and provides a network for measurable residual disease (MRD) monitoring through centralized laboratories and flow cytometry networks. ALFA's activities are primarily educational, scientific, and research-oriented rather than product-based.

Differentiator

Problem solved

Functional benefit

Brands

• Entrepôt de Données de Santé (EDS): Health Data Warehouse operated by the ALFA group for storing and managing health data related to leukemia research.

Products and services

• MRD Flow Cytometry Network Network of laboratories using LAIP/Dfn and LSC approaches for measurable residual disease (MRD) monitoring in adult AML patients, coordinated by Dr. Adriana Plesa and Dr. Christophe Roumier. Available to ALFA member clinicians and biologists across France.
• Centralized Molecular Biology Laboratory Centralized laboratory for molecular biology examinations and centralized review of mutation profiles and molecular MRD monitoring for ALFA member centers, coordinated by Pr. Claude Preudhomme at CHRU Lille.
• Centralized Cytogenetic Review Centralized review of conventional cytogenetic results for ALFA member centers, coordinated by Dr. Christine Terre at Versailles Hôpital André Mignot.
• Centralized Biobank Centralized biobank located at Lille CHRU for storing biological samples collected through ALFA clinical trials and research activities, available to member researchers.
• Data Center and Biostatistics Unit Independent data center and biostatistical unit coordinated by Prs. Sylvie Chevret and Matthieu Resche-Rigon at Paris Hôpital Saint-Louis, providing data management and statistical analysis for ALFA clinical trials.
• Translational Research Network Network of translational research laboratories animated by Pr. Raphaël Itzykson and Dr. Meyling Cheok, bridging preclinical and clinical AML research for ALFA members.
• Health Data Warehouse (Entrepôt de Données de Santé - EDS) Health Data Warehouse (Entrepôt de Données de Santé - EDS) operated by the ALFA group for storing and managing health data related to leukemia research, supporting clinical trial data management and secondary research use.
• ALFA Clinical Trials Coordination Coordination of collaborative clinical trials for adult AML patients across ALFA's 33 French member centers, including induction, consolidation chemotherapy, allogeneic stem cell transplantation, targeted therapies, and immunotherapy protocols.

Quantifiable outcome

• ALFA has contributed to over 100 peer-reviewed publications in major hematology and oncology journals

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

17 partnerships are on record, tiered core and secondary.

• Institut Carnot OPALEcoreStrategic or Co-development Partner · 10 January 2020ALFA is a founding member of the Carnot OPALE institute (Organization for Partnership Research in Leukemia). OPALE structures all preclinical and clinical French research forces for leukemia, presenting a comprehensive R&D offer to industrial companies. OPALE was labeled in February 2020 by the French Ministry for Higher Education, Research and Innovation. ALFA collaborates within OPALE alongside other cooperative groups including FILO, GRAALL, GFM, FIM, SFCE.
• FILO (French Innovative Leukemia Organization)coreStrategic or Co-development PartnerALFA collaborates closely with FILO on joint clinical studies and intergroup conferences. The ALFA-FILO Intergroup Days conference was announced for October 2026 in Bordeaux, demonstrating ongoing cooperative efforts in AML research.
• GRAALL (Group for Research on Adult Acute Lymphoblastic Leukemia)secondaryStrategic or Co-development PartnerALFA partners with GRAALL within the OPALE Carnot institute for collaborative leukemia research.
• GFM (Groupe Francophone des Myélodysplasies)secondaryStrategic or Co-development PartnerALFA partners with GFM within the OPALE Carnot institute for collaborative research.
• FIM (French Intergroup Myeloproliferative Disorders)secondaryStrategic or Co-development PartnerALFA partners with FIM within the OPALE Carnot institute for collaborative research.
• SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent)secondaryStrategic or Co-development PartnerALFA partners with SFCE within the OPALE Carnot institute for collaborative research.
• European LeukemiaNet (ELN)coreStrategic or Co-development PartnerALFA actively participates in the European LeukemiaNet MRD Working Group. ALFA contributed to the 2021 Update on MRD in AML consensus document published by the ELN MRD Working Party. ALFA's MRDflow protocols align with ELN guidelines.
• European Hematology Association (EHA)secondaryStrategic or Co-development PartnerALFA maintains institutional membership and participates in EHA congresses, contributing to European hematology research collaboration.
• American Society of Hematology (ASH)secondaryStrategic or Co-development PartnerALFA actively participates in ASH annual meetings, presenting research findings and collaborating with international hematology community.
• SFH (Société Française d'Hématologie)secondaryStrategic or Co-development PartnerALFA collaborates with SFH and participates in SFH annual congresses in France.
• SFGM-TC (Société Francophone de Greffe de Moelle et de Thérapie Cellulaire)secondaryStrategic or Co-development PartnerALFA collaborates with SFGM-TC on stem cell transplantation research and annual congresses.
• EBMT (European Society for Blood and Marrow Transplantation)secondaryStrategic or Co-development PartnerALFA participates in EBMT activities related to stem cell transplantation in AML.
• Gustave RoussysecondaryStrategic or Co-development PartnerGustave Roussy Cancer Center participates in ALFA research studies and is listed as a member center.
• Institut National du Cancer (INCa)secondaryStrategic or Co-development PartnerINCa is listed as an institutional partner on ALFA's links page, supporting cancer research initiatives.
• Force HématosecondaryStrategic or Co-development PartnerPatient advocacy organization for hematology. Force Hémato has been active for 15 years supporting leukemia research and patients.
• Institut de la Leucémie Paris Saint-LouiscoreStrategic or Co-development PartnerALFA is closely associated with the Institut de la Leucémie Paris Saint-Louis, which organized the International Leukemia Institute Symposium. Pr. Hervé Dombret serves as President of both ALFA and is affiliated with this institute. The institute hosts the Leukemia Institute Award.
• Institut CarnotcoreStrategic or Co-development PartnerALFA is part of the Institut Carnot network, specifically OPALE, which was labeled in February 2020 and brings together 17 research teams, 7 cooperative groups, and 4 R&D platforms.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• GFM (Groupe Francophone des Myélodysplasies): Direct peer within Carnot OPALE focused on myelodysplastic syndromes (MDS). Shares governance structure, partnership model, and central lab approach with ALFA, offering a directly comparable operational template.
• FILO (French Innovative Leukemia Organization): Direct peer French cooperative group focused on chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia. Partners with ALFA within Carnot OPALE on joint clinical studies and the ALFA-FILO Intergroup Days, making it the most structurally comparable peer.
• GRAALL (Group for Research on Adult Acute Lymphoblastic Leukemia): Direct peer French cooperative group for adult ALL research. Operates as a sister cooperative group within the same Carnot OPALE institute, with similar membership structure, clinical trial network, and centralized laboratory model.
• FIM (French Intergroup Myeloproliferative Disorders): Direct peer French cooperative group covering myeloproliferative neoplasms (MPN). Operates within the same Carnot OPALE framework with overlapping clinical trial coordination and member networks.
• SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent): Direct peer cooperative group within Carnot OPALE focused on pediatric leukemia. Functions with a similar member-network model and is a natural counterpart to ALFA's adult-focused AML research.

Emerging players

• ALWP (Acute Leukemia Working Party) of EBMT: Subgroup of EBMT focused on acute leukemia transplantation outcomes. Comparable as a focused working group within a larger European body, analogous to ALFA's structure within Carnot OPALE for AML research.

Broad incumbents

• EBMT (European Society for Blood and Marrow Transplantation): European society for stem cell transplantation research and registry. ALFA participates in EBMT activities related to AML transplantation, making it a broader incumbent peer in the AML/transplant research ecosystem.
• EORTC (European Organisation for Research and Treatment of Cancer): Pan-European intergroup conducting clinical trials across multiple cancer types including hematological malignancies. Comparable as a larger cooperative group that competes with national groups like ALFA for pan-European AML trial sponsorship.
• European LeukemiaNet (ELN): Pan-European leukemia research network that publishes AML guidelines and MRD consensus standards. ALFA's MRDflow protocols align with ELN guidelines, making ELN a broader incumbent peer governing the standards ALFA's work adheres to.

Regional players

• GOELAMS (Groupe Ouest-Est des Leucémies et Autres Maladies du Sang): Historical French cooperative group for leukemia research that eventually merged into current French leukemia research structures. Comparable as a regional French peer in adult hematology research networks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alfa-acute-leukemia-french-association

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALFA - Acute Leukemia French Association